{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:23:06Z","timestamp":1767208986955,"version":"build-2238731810"},"reference-count":19,"publisher":"American Society of Consultant Pharmacists","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To describe the case of an 88-year-old male with rheumatoid arthritis who developed pulmonary manifestations. Treatment for his RA previously included various biologics, while at the time of pulmonary consultation included meloxicam, methotrexate, and abatacept.\n Following chest scans, bronchoscopy, needle biopsy, pulmonary function testing, and a thoracentesis, the diagnosis of pleural effusion and nodules associated with rheumatoid arthritis was determined. The patient was recommended to follow-up with the pulmonologist but was lost to follow-up\n because of nonpulmonary and nonrheumatoid arthritis complications.\n                    <jats:bold>Settings<\/jats:bold>\n                    Ambulatory clinic pharmacy practice, Community pharmacy, Consultant pharmacy practice.\n                    <jats:bold>Practice Considerations<\/jats:bold>\n                    Drugs used to treat rheumatoid arthritis may produce pulmonary\n toxicity similar to what is seen with the disease itself. Drug therapy may require modification if identified as an offending agent causing pulmonary manifestations. If fibrosing interstitial lung disease develops, the addition of nintedanib may need to be considered.\n                    <jats:bold>Conclusion<\/jats:bold>\n                    In order for pharmacists to better assist providers and patients and improve therapeutic outcomes, it is important for pharmacists to understand that pulmonary manifestations are common in patients having rheumatoid arthritis as well as with drugs used to treat rheumatoid arthritis.\n                  <\/jats:p>","DOI":"10.4140\/tcp.n.2021.97","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:31:22Z","timestamp":1630110682000},"page":"97-103","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary Manifestations of Rheumatoid Arthritis"],"prefix":"10.4140","volume":"36","author":[{"given":"Keith J.","family":"Christensen","sequence":"first","affiliation":[{"name":"1Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Malesker","sequence":"additional","affiliation":[{"name":"1Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Jagan","sequence":"additional","affiliation":[{"name":"2Creighton University School of Medicine, Omaha, Nebraska."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R","family":"Moore","sequence":"additional","affiliation":[{"name":"2Creighton University School of Medicine, Omaha, Nebraska."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","year":"2019"},{"key":"ref2","article-title":"Clinical, epidemiological, and histopathological features of respiratory involvement in rheumatoid arthritis.","year":"2017","journal-title":"BioMed Res Int."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0034-1371543","article-title":"Pulmonary pathology in connective tissue dDiseases.","volume":"35","year":"2014","journal-title":"Semin Respir Crit Care Med."},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3899\/jrheum.150166","article-title":"A study of multiple causes of death in rheumatoid arthritis.","volume":"42","year":"2015","journal-title":"J Rheumatol"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chest.2017.05.015","article-title":"Lung manifestations in the rheumatic diseases.","volume":"152","year":"2017","journal-title":"Chest."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.semarthrit.2017.09.005","article-title":"Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: a marginal structural model analysis in the Nurses\u2019 Health Study.","volume":"47","year":"2018","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.13-2388","article-title":"Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia.","volume":"146","year":"2014","journal-title":"Chest."},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population based study.","volume":"62","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.","volume":"366","year":"2012","journal-title":"N Engl J Med."},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease.","volume":"379","year":"2018","journal-title":"N Engl J Med."},{"issue":"13","key":"ref11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review.","volume":"320","year":"2018","journal-title":"JAMA."},{"key":"ref12","year":"2018"},{"key":"ref13","year":"2018"},{"key":"ref14","year":"2018"},{"issue":"1","key":"ref15","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"68","year":"2015","journal-title":"Arthritis Care Res."},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review.","volume":"43","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"ref17","article-title":"\u201cPneumotox\u201d","year":"2020"},{"key":"ref18","year":"2019"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases.","volume":"381","year":"2019","journal-title":"N Engl J Med."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2021\/00000036\/00000002\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T23:33:45Z","timestamp":1645659225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2021.97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":19,"aliases":["10.4140\/tcp.n.2021.97."],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["2639-9636(20210201)36:2L.97;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2021.97","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}